Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

Press Release

New York and Vancouver, BC –  May 28, 2025 – Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Ian McDonald, Chief Executive Officer, and…

Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025

Press Release

– Key Opinion Leaders (KOLs) on Absence seizures include Dennis Dlugos, MD, Wendyl D’Souza, MBChB, MPH, FRACP, PhD, and Alexander Rotenberg, MD, PhD –   Vancouver, British Columbia, May 20, 2025 – Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a company focused on developing highly selective 5-HT2 agonists for…

Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101

Press Release

BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model – The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) – Findings highlight BMB-101’s potential to address critical gaps in SUDEP prevention –   New York and Vancouver, British Columbia, May 13, 2025 – Bright Minds Biosciences Inc.…